Search - tctmd.com

Displaying 21 - 40 of 126

Sort: Relevancy | Date

Presentation TCT 2025

TCT 534: Circulatory Assist Devices in HFrEF: Assessing 30-Day Major Adverse Cardiovascular Events and Clinical Outcomes

Presenter: Mohamed Elhussain

October 27, 2025

Presentation TCT 2025

TCT 558: Low Filling Pressures in Patients with Acute Exacerbation of Heart Failure with Reduced Ejection Fraction (HFrEF) as Identified with a Novel Sensor: A Sub-Analysis of the SEISMIC-HF I Study

Presenter: Anjan Tibrewala

October 26, 2025

Presentation TCT 2025

TCT 1411: HFrEF: A Long-Term Journey Marked by One Narrow Escape After Another

Presenter: Sunanto Ng

October 26, 2025

Presentation TCT 2025

TCT 1777: Refractory HFrEF Salvaged by Atrial Flow Regulator

Presenter: Mega Febrianora

October 25, 2025

Presentation NY Valves 2025

Case Resolution

Presenter: Ilan Richter

June 26, 2025

Presentation NY Valves 2025

From the Base of the Papillary Muscles: V-SLING

Presenter: Horst Sievert

June 26, 2025

Presentation NY Valves 2025

Using an Epicardial Approach: CARILLON Updates

Presenter: Samir R. Kapadia

June 26, 2025

Presentation NY Valves 2025

From Inside the LV: ANCORA Updates

Presenter: Ulrich P. Jorde

June 26, 2025

Presentation NY Valves 2025

Case Presentation: 65 year old Woman with Symptomatic HFrEF Refractory to Optimal GDMT

Presenter: Ilan Richter

June 26, 2025

Presentation NY Valves 2025

Is LV Reconstruction a Viable Therapy to Treat the Dilated Heart?

Presenter: Michael I. Brener

June 26, 2025

Presentation THT 2025

Stem Cell Based Therapies for HFpEF and HFrEF

Presenter: Sunjay Kushal

February 12, 2025

Presentation THT 2025

Controlled Pulmonary Artery Banding for HFrEF (Restore Medical)

Presenter: Sean Pinney

February 12, 2025

Presentation THT 2025

Transcatheter Pulmonary Artery Banding [PAB] for HFrEF: Two Year Follow Up and Invasive Exercise Hemodynamics From the Ongoing First-In-Human Trial

Presenter: Sean Pinney

February 12, 2025

Presentation THT 2025

Interatrial Shunts and the HFrEF - HFpEF Divide: The Differential Effects in RELIEVE-HF Explained?

Presenter: JoAnn Lindenfeld

February 12, 2025

Presentation THT 2025

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 12, 2025

Presentation THT Abstracts 2025

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Presentation THT Abstracts 2025

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Presenter: Ibrahim Kamel

February 11, 2025

Presentation THT 2025

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Presenter: Gregg W. Stone

February 11, 2025

Presentation THT 2025

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Presenter: Jonathan Zawadzki

February 11, 2025

Advertisement

TCT 534: Circulatory Assist Devices in HFrEF: Assessing 30-Day Major Adverse Cardiovascular Events and Clinical Outcomes

TCT 558: Low Filling Pressures in Patients with Acute Exacerbation of Heart Failure with Reduced Ejection Fraction (HFrEF) as Identified with a Novel Sensor: A Sub-Analysis of the SEISMIC-HF I Study

TCT 1411: HFrEF: A Long-Term Journey Marked by One Narrow Escape After Another

TCT 1777: Refractory HFrEF Salvaged by Atrial Flow Regulator

Case Resolution

From the Base of the Papillary Muscles: V-SLING

Using an Epicardial Approach: CARILLON Updates

From Inside the LV: ANCORA Updates

Case Presentation: 65 year old Woman with Symptomatic HFrEF Refractory to Optimal GDMT

Is LV Reconstruction a Viable Therapy to Treat the Dilated Heart?

Stem Cell Based Therapies for HFpEF and HFrEF

Controlled Pulmonary Artery Banding for HFrEF (Restore Medical)

Transcatheter Pulmonary Artery Banding [PAB] for HFrEF: Two Year Follow Up and Invasive Exercise Hemodynamics From the Ongoing First-In-Human Trial

Interatrial Shunts and the HFrEF - HFpEF Divide: The Differential Effects in RELIEVE-HF Explained?

Impact of SGLT2 Inhibitors on Mortality and Cardiovascular Admissions in Heart Failure With Reduced Ejection Fraction (HFrEF)

Association of SGLT2 Inhibitors With Clinical Outcomes in Patients With Severe Renal Impairment (Estimated Glomerular Filtration Rate < 30) and Heart Failure With Reduced Ejection Fraction (HFrEF)

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Disparities in MDD Incidence Between HFpEF and HFrEF Patients

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Impact of Psychological Comorbidities on Clinical Outcomes in Heart Failure With Reduced Ejection Fraction (HFrEF)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content